Alterola Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-2.78	-2.37	-2.07	-6.47	-0.31
Stock-Based Compensation	0.34	0.54	0.8	5.76	0.24
Change in Inventory	-0	-0	0	-0	-
Change in Accounts Payable	0.09	0.22	0.07	0.44	-
Change in Other Net Operating Assets	0.24	0.17	-0.11	0.31	0.02
Operating Cash Flow	-2.32	-1.45	-1.31	0.04	-0.05
Short-Term Debt Issued	-	1.47	1.15	-	0.05
Long-Term Debt Issued	-	-	-	0.16	-
Total Debt Issued	3.72	1.47	1.15	0.16	0.05
Short-Term Debt Repaid	-	-	-	-0.54	-
Total Debt Repaid	-1.06	-	-	-0.54	-
Net Debt Issued (Repaid)	2.66	1.47	1.15	-0.38	0.05
Issuance of Common Stock	0.21	-	0.05	0.37	-
Other Financing Activities	-0.16	-	-	-0	-
Financing Cash Flow	2.72	1.47	1.2	-0.01	0.05
Foreign Exchange Rate Adjustments	-0.23	-0.03	0.05	0.03	-
Net Cash Flow	0.07	-0.01	-0.05	0.06	-
Levered Free Cash Flow	-2.13	-0.43	-0.51	1.91	-
Unlevered Free Cash Flow	-1.92	-0.43	-0.51	1.91	-
Change in Working Capital	0.33	0.39	-0.04	0.76	0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.